Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases, has an upcoming data readout that you should watch out for.
The company's lead drug candidate is Lanifibranor, the only pan-PPAR (peroxisome proliferator-activated receptor) agonist in clinical development for Non-alcoholic steatohepatitis (NASH).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com